PCSK9 inhibitors and modern lipid therapy explained

Lipid management is a foundation of cardiovascular disease prevention. Lower LDL cholesterol is associated with lower cardiovascular event risk, and the relationship is consistent across populations and across the LDL range. The clinical question for each patient is what LDL level to aim for and what combination of medicines to use to get there.

The foundational role of statins. Statins (atorvastatin, rosuvastatin, simvastatin, others) lower LDL cholesterol substantially and are the foundation for nearly all patients who need lipid-lowering therapy. They have decades of outcomes evidence, are well-tolerated for most patients, and are inexpensive. Most modern guidelines call for high-intensity statin therapy for patients with established cardiovascular disease and for selected primary-prevention patients at high risk.

What happens when statins are not enough. Some patients cannot reach target LDL on maximally-tolerated statin therapy alone, either because they have very high baseline levels (often genetic, as in familial hypercholesterolemia) or because they cannot tolerate higher statin doses. Some patients cannot tolerate statins at all. For these patients, add-on therapy is needed.

The add-on options.

Ezetimibe: an oral medicine that inhibits cholesterol absorption from the intestine. Adds a modest LDL reduction on top of statin therapy. Often used as a first add-on because it is oral, inexpensive, and well-tolerated.

PCSK9 inhibitors: a major addition to the lipid-management toolkit. PCSK9 is a protein that breaks down LDL receptors on liver cells. LDL receptors are what remove LDL cholesterol from the blood. Reducing PCSK9 means more LDL receptors available, which means more LDL cleared from the blood.

The injectable PCSK9 monoclonal antibodies (alirocumab, evolocumab) bind and neutralise PCSK9 protein. They are given as injections every 2 to 4 weeks. They produce substantial additional LDL reduction on top of statin and outcome trials show cardiovascular benefit.

Inclisiran is a different approach to PCSK9 inhibition. It is a small interfering RNA medicine that reduces PCSK9 production in the liver. It is given as an injection just twice a year after initial doses, which simplifies long-term therapy substantially.

Bempedoic acid is an oral non-statin medicine that works upstream of statins in cholesterol synthesis. It is particularly useful for patients who cannot tolerate statins.

Lp(a)-targeted therapy. Lipoprotein(a) is a separate lipid particle from LDL that carries independent cardiovascular risk. Lp(a) levels are largely genetically determined and are not lowered by statins. New medicines (pelacarsen, lepodisiran, olpasiran) reduce Lp(a) substantially through different RNA-based approaches; their cardiovascular outcomes trials are reading out, and if positive, would establish a new lipid-target category.

The emerging direction. Oral PCSK9 inhibitors are in late-stage trials, with the proposition of high-efficacy LDL reduction without injection delivery. ANGPTL3-targeted medicines extend the addressable lipid-target set further.

What to expect. The combination of lipid-lowering options has expanded substantially in the past five years. Most patients can reach appropriate LDL targets with the right combination, and the long-term cardiovascular benefit of getting there is well-established. The conversation with a clinician centres on individual cardiovascular risk, current LDL level, response to existing therapy, and tolerability, with the modern toolkit providing meaningful flexibility.